Form 4: Vistagen Therapeutics Director Jerry Gin Acquires 12,500 Stock Options
SEC Form 4 Filing
Director Jerry Gin acquired 12,500 stock options in Vistagen Therapeutics, Inc. on March 4, 2024, according to a Form 4 filing.
Summary
- On March 4, 2024, Jerry Gin, a director of Vistagen Therapeutics, Inc., acquired 12,500 stock options.
- The options were granted under the company's Amended and Restated 2019 Omnibus Equity Incentive Plan.
- The exercise price of the options is $4.85.
- The options vest in twelve equal monthly installments, starting on the grant date.
- The options expire on March 4, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The grant itself can be seen as a positive, but the filing is routine.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2023-09-08 | Date of Power of Attorney execution. |
| 2024-03-04 | Date of stock option grant. |
| 2024-03-06 | Date of Form 4 filing. |
| 2034-03-04 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.